Dominik Heger - Fresenius Medical Strategic Relations
| 0H9X Stock | 46.31 0.75 1.65% |
Executive
Dominik Heger is Strategic Relations of Fresenius Medical Care
| Address | Else-Kröner-Strasse 1, Bad Homburg, Germany, 61352 |
| Phone | 49 6172 609 0 |
| Web | https://www.freseniusmedicalcare.com |
Fresenius Medical Management Efficiency
The company has return on total asset (ROA) of 0.0285 % which means that it generated a profit of $0.0285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0484 %, meaning that it generated $0.0484 on every $100 dollars invested by stockholders. Fresenius Medical's management efficiency ratios could be used to measure how well Fresenius Medical manages its routine affairs as well as how well it operates its assets and liabilities. Total Assets is likely to drop to about 30.9 B in 2025. Other Assets is likely to drop to about 1.1 B in 2025Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Pamela Erickson | Raytheon Technologies Corp | N/A | |
| Olivier Guitard | Sartorius Stedim Biotech | N/A | |
| Phil Baldock | Technicolor | N/A | |
| Juan Bedout | Raytheon Technologies Corp | N/A | |
| Dantaya Williams | Raytheon Technologies Corp | 49 | |
| Wesley Kremer | Raytheon Technologies Corp | 59 | |
| Catherine Kuttner | Technicolor | N/A | |
| Alexander Foltin | Infineon Technologies AG | 56 | |
| Alice HeezenDokianos | Synthomer plc | 55 | |
| Benedikt Orzelek | Sartorius Stedim Biotech | N/A | |
| Aline Bourcereau | Technicolor | N/A | |
| Philip Wrigley | Synthomer plc | N/A | |
| Kimberly Scardino | Home Depot | 54 | |
| Lars Ihlen | Technicolor | 50 | |
| AnnMarie Campbell | Home Depot | 59 | |
| Neil Mitchill | Raytheon Technologies Corp | 49 | |
| Pat Byrne | Technicolor | 62 | |
| MSc MBA | Synthomer plc | N/A | |
| Jennifer Reed | Raytheon Technologies Corp | N/A | |
| Bernd Hops | Infineon Technologies AG | 51 | |
| Amy Johnson | Raytheon Technologies Corp | 49 | |
Management Performance
| Return On Equity | 0.0484 | ||||
| Return On Asset | 0.0285 |
Fresenius Medical Care Leadership Team
Elected by the shareholders, the Fresenius Medical's board of directors comprises two types of representatives: Fresenius Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresenius. The board's role is to monitor Fresenius Medical's management team and ensure that shareholders' interests are well served. Fresenius Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresenius Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oliver Maier, Senior Relations | ||
| Helen Giza, Chief CEO | ||
| Roberto Fuste, Executive Strategy | ||
| Charlotte Stange, VP Sustainability | ||
| Nwamaka MD, Head Operations | ||
| GailSuzanne Brown, Senior Development | ||
| Katarzyna MazurHofsab, Management AG | ||
| Borries Muller, Senior Communications | ||
| FACHE MBA, CEO Board | ||
| Joachim Weith, Senior Affairs | ||
| Robert Powell, Member AG | ||
| Franklin FACP, Global Board | ||
| Dominik Heger, Strategic Relations | ||
| Martin Fischer, CFO Board | ||
| Glenn Slater, Senior Operations | ||
| William Valle, Management AG | ||
| Thomos Dimt, Executive EMEALA | ||
| Horst Radtke, Executive America | ||
| Jorg Haring, Compliance Legal | ||
| Gunther Klotz, Executive Europe | ||
| Wolfgang Kummerle, Senior International | ||
| David Kembel, Chief America |
Fresenius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fresenius Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0484 | ||||
| Return On Asset | 0.0285 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 24.36 B | ||||
| Shares Owned By Insiders | 32.16 % | ||||
| Shares Owned By Institutions | 37.51 % | ||||
| Revenue | 19.34 B | ||||
| Gross Profit | 4.76 B | ||||
| EBITDA | 2.35 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Fresenius Stock Analysis
When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.